NASDAQ$LYEL
Lyell Immunopharma Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Lyell Immunopharma's financial results for Q2 2023 were reported, and business highlights were discussed.
Lyell Immunopharma reported a net loss of $63.9 million for the second quarter ended June 30, 2023, compared to a net loss of $36.3 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $632.7 million as of June 30, 2023. Initial clinical data from two lead product candidates are expected in 2024.
- Cash, cash equivalents and marketable securities totaled $632.7 million as of June 30, 2023.
- The company remains on track for initial clinical data from two lead product candidates in 2024.
- Matt Lang, J.D., was appointed as Chief Business Officer.
- Lyell is advancing four wholly-owned product candidates with two product candidates in Phase 1 clinical development, LYL797 and LYL845.
Headline financials
Revenue & EPS history
Lyell Immunopharma · Revenue · Quarterly
$27K
Forward guidance
Lyell anticipates progress in its business plans, strategy, and clinical trials, with expectations of financial stability into 2026.
Tailwinds
- Lyell’s anticipated progress, business plans, business strategy and clinical trials
- Lyell’s advancement of its pipeline or its research, development and clinical capabilities
- The potential clinical benefits and therapeutic potential of Lyell’s product candidates
- The advancement of Lyell’s technology platform
- Lyell’s expectation that its financial position and cash runway will support advancement of its pipeline into 2026
Headwinds
- The effects of geopolitical instability
- Macroeconomic conditions and the lingering effects of the COVID-19 pandemic
- Lyell’s ability to submit planned INDs or initiate or progress clinical trials on the anticipated timelines, if at all
- Lyell’s limited experience as a company in enrolling and conducting clinical trials, and lack of experience in completing clinical trials
- Lyell’s ability to manufacture and supply its product candidates for its clinical trials
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.5%
Avg return
Earnings day
-4.0%
Avg return
5 days after
+1.1%
Avg return
30 days after
73%
16 / 22 earnings
Positive
+20.3%
Q4 2024
Best reaction
-18.3%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.1% | -7.0% | -42.1% | |
| Q4 2025 | +2.5% | -19.0% | -9.6% | |
| Q3 2025 | -1.3% | +1.7% | +95.5% | |
| Q1 2025 | +4.6% | +2.0% | +21.1% | |
| Q4 2024 | +20.3% | +15.5% | -10.3% | |
| Q3 2024 | -17.6% | -21.3% | -38.9% | |
| Q2 2024 | +1.4% | -8.1% | -20.9% | |
| Q1 2024 | +7.6% | +4.2% | +13.6% | |
| Q4 2023 | +2.5% | -8.6% | -21.8% | |
| Q3 2023 | +6.8% | -24.8% | -11.8% | |
| Q2 2023 | +1.5% | -1.9% | -16.8% | |
| Q1 2023 | +6.9% | +6.5% | +50.9% | |
| Q4 2022 | +9.6% | +1.4% | -1.8% | |
| Q3 2022 | -18.3% | -17.0% | -28.8% | |
| Q2 2022 | +16.3% | +20.2% | +10.1% | |
| Q1 2021 | -12.4% | -22.8% | +1.5% | |
| Q1 2022 | -12.4% | -22.8% | +1.5% | |
| Q4 2019 | +6.1% | +6.1% | +1.6% | |
| Q4 2021 | +6.1% | +6.1% | +1.6% | |
| Q3 2021 | -4.1% | -3.6% | -18.8% | |
| Q4 2020 | +2.8% | +2.2% | +24.6% | |
| Q2 2021 | +2.8% | +2.2% | +24.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro